Cutting-Edge Innovations and Clinical Impact of CAR-Based Cancer Immunotherapy

Dear Colleagues,

Adoptive cell therapy (ACT) represents a groundbreaking approach in cancer treatment, involving the engineering and expansion of a patient’s immune cells ex vivo before reinfusion to target cancer cells. Among ACT, chimeric antigen receptor T-cells (CAR-T) have revolutionized the treatment of hematological malignancies. However, the success of CAR-T therapy in solid tumors remains limited due to challenges such as antigen heterogeneity, T-cell exhaustion, poor tumor infiltration, and the immunosuppressive tumor microenvironment. Additionally, managing adverse events like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) continues to be a critical focus. Therefore, substantial opportunities exist for improvement, and ongoing efforts are focused on designing the next generation of CAR-based cellular immunotherapies, aiming to enhance the efficacy and safety of these cell therapies. 

We invite submissions of original research articles and reviews that explore the latest advancements in CAR-based immunotherapies for hematological malignancies, solid tumors, and beyond, such as in autoimmune diseases. Topics include emerging trends in any area of experimental and computational biology, including but not limited to biomarkers for CAR-based therapies, multiplexing CAR constructs, CAR-based combination therapies, chimeric engulfment receptor (CER) technology, DC- and Treg-based immunotherapies, and novel in vivo CAR approaches. We also welcome studies on CAR therapies in various immune cell types, including macrophages (CAR-M or CAR-P) and NK cells (CAR-NK). Submissions should present significant conceptual advances or raise important questions and hypotheses, aiming to drive forward the field of CAR-based cellular immunotherapies.

Dr. Deepesh Kumar Gupta
Dr. Ezhilarasi Chendamarai
Dr. Abhinava Mishra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.